- Home
- ARGX
ARGX
argenx SE
as 01-17-2025 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 37.3B | IPO Year: | 2017 |
| Target Price: | $653.11 | AVG Volume (30 days): | 258.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $349.86 - $678.21 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,908,659,000 | Revenue Growth: | 85.56% |
| Revenue Growth (this year): | 70.98% | Revenue Growth (next year): | 51.22% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Earnings Estimates Rising for Argenx (ARGX): Will It Gain?
GlobeNewswire
8 days ago
argenx Highlights 2025 Strategic Priorities
GlobeNewswire
15 days ago
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
20 days ago
Exploring High Growth Tech Stocks for January 2025
TipRanks
24 days ago
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment
MT Newswires
25 days ago
Wedbush Raises Argenx's Price Target to $665 From $655, Maintains Outperform Rating
MT Newswires
25 days ago
Argenx Says Japan Approves Vyvdura Injection for Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewswire
25 days ago
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.